| Literature DB >> 26968550 |
Hongli Zhu1, Wenyan Xu1, Hong Liu1, Huaquan Wang1, Rong Fu1, Yuhong Wu1, Wen Qu1, Guojin Wang1, Jing Guan1, Jia Song1, Limin Xing2, Zonghong Shao3.
Abstract
To investigate the expression of activation molecules on CD5(+)B lymphocytes in peripheral blood of autoimmune hemolytic anemia (AIHA)/Evans patients. The expression of CD80, CD86, and CD69 on CD5(+)B lymphocytes was detected using flow cytometry in 30 AIHA/Evans patients, 18 normal controls (NC) and nine chronic lymphocytic leukemia (CLL) patients. CD80 on CD5(+)B lymphocytes in untreated patients was higher than that in remission patients (P < 0.05), NC (P < 0.01) and CLL patients (P < 0.01). CD80 on CD5(+)B lymphocytes was higher than that on CD5(-)B lymphocytes in untreated patients (P > 0.05), but lower than those of CD5(-)B lymphocytes in remission patients and NC (P < 0.05). CD86 on CD5(+)B lymphocytes of untreated patients was higher than that of remission patients (P < 0.05), NC (P < 0.01). CD86 on CD5(+)B lymphocytes of CLL was higher than that of NC, remission (P < 0.05), and untreated patients (P > 0.05). CD80 and CD86 on CD5(+)B lymphocytes was negatively correlated with hemoglobin (HB), C3, C4 (P < 0.05) and positively correlated with reticulocyte (Ret) (P < 0.05). CD69 on CD5(+) and CD5(-)B lymphocytes of CLL was higher than those of AIHA/Evans patients and NC (P < 0.05). The active molecules on CD5(+)B lymphocytes in peripheral blood of AIHA/Evans patients differ from those on CD5(-) and clonal CD5(+)B lymphocytes.Entities:
Keywords: Autoimmune hemolytic anemia; CD5+B lymphocytes; CD69; CD80; CD86
Mesh：
Substances：
Year: 2016 PMID： 26968550 DOI： 10.1007/s12185-016-1964-8
Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490